- ALOXI® is recommended for acute and delayed emesis prevention
when using moderate emetic risk chemotherapy.*
- ALOXI is superior to other 5-HT3 antagonists for preventing
delayed nausea.
- The addition of dexamethasone improves the efficacy
of the antiemetic regimen containing 5-HT3 antagonists. Ondansetron, granisetron,
and dolasetron are effective in preventing acute emesis but appear to be less effective
for delayed emesis. However, ALOXI is effective for preventing both delayed and
acute emesis.
*NCCN Consensus Category 1: Uniform NCCN consensus, based on high-level evidence,
that the recommendation is appropriate.
NCCN is a registered trademark of the National Comprehensive Cancer Network.
Reference
- NCCN® Practice Guidelines in Oncology – v.1.2007: Antiemesis. National Comprehensive
Cancer Network. Available at: http:/www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf. Accessed March 2, 2007.